Risk factors analysis on rebleeding after bronchial artery embolization

doi:10.3877/cma.j.issn.2095-5782.2014.02.011

Abstract

Abstract:

Objective

To investigate the risk factors and correlation of rebleeding after bronchial artery embolization (BAE) in patients with hemoptysis.

Methods

Seventy-five patients with hemoptysis who were treated with BAE were divided into two groups based on with or without rebleeding after BAE. Comparison and correlation on the influence of different factors such as age, gender, protopathy, pathogenesis, amount of bleeding, emboliaztion agents, angiography and so on were analyzed in detail.

Results

Rebleeding after BAE were diagnosed in 17.33% (13/75) cases. During all the factors, only the bronchial-pulmonary artery/vein shunt between the two groups showed significant difference. Other factors such as age, gender, protopathy, pathogenesis, amount of bleeding, emboliaztion agents have no difference. Multivariate regression analysis justified esophageal fistula was strongly related to post operative hemorrhage.

Conclusions

Bronchial-pulmonary artery/vein shunt is the main risk factor of rebleeding after BAE.

Key words: Embolization, therapeutic, Hemoptysis, Risk factors

Ming Shan, Zhihui Chang, Chuanzhuo Wang, Zhaoyu Liu. Risk factors analysis on rebleeding after bronchial artery embolization[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2014, 02(02): 40-43.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2014.02.011

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2014/V02/I02/40

Figures/Tables 3

References 12

1	王超，吕永兴，邹英华．超选择性支气管动脉栓塞治疗大咯血的临床评价[J]．介入放射学杂志，2008，17(10): 737-739．
2	Marshall TJ, Jackson JE. Vascular intervention in the thorax: bronchial artery embolization for hemoptysis[J]. Eur Radiol, 1997,7(8):1221-1227.
3	Katoh O, Kishikawa T, Yamada H, et al. Recurrent bleeding after arterial embolization in patients with hemoptysis[J]. Chest, 1990,97(3):541-546.
4	oon W, Kim JK, Kim YH, et al. Bronchial and non-bronchial systemic artery mbolization for life-threatening hemoptysis: a comprehensive review[J]. Radiographics, 2002,22(6):1395-1409.
5	Haponik EF, Fein A, Chin R. Managing life-threatening hemoptysis: has anything really changed[J]? Chest, 2000,118(5):1431-1435.
6	Corr P. Management of severe hemoptysis from pulmonary aspergilloma using endovascular embolization[J]. Cardiovasc Intervent Radiol, 2006,29(5):807-810.
7	van den Heuvel MM, Els Z, Koegelenberg CF, et al. Risk factors for recurrence of haemoptysis following bronchial artery embolisation for life-threatening haemoptysis[J]. Int J Tuberc Lung Dis, 2007,11(8):909-914.
8	陈平有，仇俊华，杨守俊，等．经导管支气管动脉栓塞术治疗咯血术后复发的原因及预防[J]．中国介入影像与治疗学，2010，7(6): 613-616．
9	Lee EW, Grant JD, Loh CT, et al. Bronchial and pulmonary arterial and venous interventions[J]. Semin Respir Crit Care Med, 2008,29(4):395-404.
10	屈国林，强民，唐晖，等．支气管动脉介入治疗的栓塞剂选择和应用[J]．实用诊断与治疗杂志，2007，21(3): 164-167.
11	Yoo DH,Yoon CJ,Kang SG, et al. Bronchial and nonbronchial systemic artery embolization in patients with major hemoptysis: safety and efficacyof N-butyl cyanoacrylate[J]. AJR Am J Roentgenol, 2011, 196(2):W199-204.
12	Osaki S,Nakanishi Y,Wataya H, et al. Prognosis of bronchial artery embolization in the management of hemoptysis[J]. Respiration, 2000,67(4):412-416.

基本资料		例数
病因		?
?	支气管扩张	51
?	肺结核	12
?	肺癌	7
?	肺转移癌	2
?	纵隔肿瘤放疗后	2
?	病因不明	1
病变范围		?
?	单发（局限一个肺叶内）	41
?	多发（多肺叶受累）	34
支气管动脉造影表现		?
?	支气管-肺动/静脉分流	36
?	血管增粗、新生血管	69
?	造影剂外溢	2
栓塞剂		?
?	明胶海绵	61
?	KMG颗粒	14

基本资料		例数
病因		?
?	支气管扩张	51
?	肺结核	12
?	肺癌	7
?	肺转移癌	2
?	纵隔肿瘤放疗后	2
?	病因不明	1
病变范围		?
?	单发（局限一个肺叶内）	41
?	多发（多肺叶受累）	34
支气管动脉造影表现		?
?	支气管-肺动/静脉分流	36
?	血管增粗、新生血管	69
?	造影剂外溢	2
栓塞剂		?
?	明胶海绵	61
?	KMG颗粒	14

对比项目	出血组（n=13）	无出血组（n=62）	P值
年龄（岁）	60.5（45 ~ 79）	59.0（35 ~ 83）	0.813
男/女（例）	8/5	44/18	0.612
良性/恶性（例）	10/3	54/8	0.327
单发/多发（例）	7/6	54/8	0.145
病程1年以内/1年以上（例）	8/5	35/27	0.168
明胶海绵/KMG颗粒（例）	10/3	51/11	0.069
分流有/无（例）	11/2	25/37	0.027
术前24 h咯血量≤ 300 ml/>300 ml（例）	6/7	29/33	0.726

对比项目	出血组（n=13）	无出血组（n=62）	P值
年龄（岁）	60.5（45 ~ 79）	59.0（35 ~ 83）	0.813
男/女（例）	8/5	44/18	0.612
良性/恶性（例）	10/3	54/8	0.327
单发/多发（例）	7/6	54/8	0.145
病程1年以内/1年以上（例）	8/5	35/27	0.168
明胶海绵/KMG颗粒（例）	10/3	51/11	0.069
分流有/无（例）	11/2	25/37	0.027
术前24 h咯血量≤ 300 ml/>300 ml（例）	6/7	29/33	0.726

变量	优势比（OR值）	95%可信区间（CI）	P值
年龄	1.23	0.81-3.70	0.74
性别	1.80	0.59-5.83	0.37
病因	1.89	0.51-7.32	0.36
病变范围	2.27	0.68-8.21	0.18
病程	2.07	0.50-8.17	0.21
栓塞剂	3.56	0.95-13.21	0.07
术前24 h咯血量	1.85	0.83-12.88	0.39
分流	5.58	1.64-22.2	0.01

Please choose a citation manager

Content to export